Brian Wolpin

38PUBLICATIONS
502CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosisGene mappingPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|Aug 11, 2026
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.

|Jul 08, 2026
Impact of vitamin D on the colon cancer immune microenvironment: results of a randomized clinical trial of preoperative vitamin D supplementation in patients with stage I-III colon cancer.

|May 25, 2026
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.

|Mar 23, 2026
Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery Study.

Ann L Oberg, William R Bamlet, Grant Izmirlian

|Feb 13, 2026
A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.

Brandon M Huffman, Miklos Diossy, Matthew B Yurgelun

|Sep 10, 2025
PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.

Jennifer J Knox, Grainne O'Kane, Daniel King

Pageof 7

Frequent Collaborators

24 joint publications

Andrew J Aguirre

14 joint publications

Kimberly Perez

14 joint publications

Kimmie Ng

14 joint publications

Harshabad Singh